Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Randomized Placebo-controlled Study to Assess the Impact on Outcome of Eltrombopag Administered to Elderly Patients with Acute Myeloid Leukemia Receiving Induction Chemotherapy

NCT03603795 is registered in ClinicalTrials.gov with French Innovative Leukemia Organisation as lead sponsor.

NCT NCT03603795
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03603795 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Randomized Placebo-controlled Study to Assess the Impact on Outcome of Eltrombopag Administered to Elderly Patients with Acute Myeloid Leukemia Receiving Induction Chemotherapy
Lead sponsor
French Innovative Leukemia Organisation
Phase
Phase 2
Overall status
Active, not recruiting
Start date
October 11, 2018
Completion date
July 30, 2026
Enrollment
110 (estimated)
Sites
15

Conditions

As the registry lists them; a condition with its own page is linked.

acute myeloid leukemia